Optimizing Phosphopeptide Structures That Target 14-3-3ε in Cutaneous Squamous Cell Carcinoma

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• 14-3-3ε protein is implicated in various cancers, including cutaneous squamous cell carcinoma (cSCC).
• In cSCC, 14-3-3ε overexpression and cytoplasmic mislocalization lead to interaction with CDC25A, suppressing apoptosis.
• Inhibiting the 14-3-3ε-CDC25A interaction is a promising therapeutic strategy for cSCC.

Purpose of the Study:

• To optimize a previously designed phosphopeptide inhibitor (pT) targeting the 14-3-3ε-CDC25A interaction.
• To develop novel peptide analogs with enhanced binding affinity to 14-3-3ε.
• To evaluate the potential of these analogs as therapeutic agents for cSCC.

Main Methods:

• Peptide design and synthesis, including shortening and site-specific modifications.
• Molecular dynamics (MD) simulations to analyze peptide-protein interactions.
• Biophysical methods (e.g., measuring K_D values) to determine binding affinities.

Main Results:

• A shortened peptide analog, pT(502-510), exhibited nanomolar affinity (K_D: 45.2 nM) for 14-3-3ε.
• A further modified analog with a Gly to Phe substitution at position 510 demonstrated improved affinity (K_D: 22.0 nM).
• These optimized peptides effectively bind to 14-3-3ε.

Conclusions:

• The designed peptide analogs are potent inhibitors of the 14-3-3ε-CDC25A interaction.
• These peptides represent potential therapeutic candidates for inducing apoptosis in cSCC cells.
• Further investigation into their efficacy in cSCC treatment is warranted.